New drug cocktail aims to outsmart resistant prostate cancer
NCT ID NCT04986423
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2b trial tests whether adding an experimental drug called ZEN003694 to the standard drug enzalutamide can help men with metastatic castration-resistant prostate cancer that has stopped responding to abiraterone. About 200 men will be randomly assigned to receive either the combination or enzalutamide alone. The study separates patients based on how well they responded to prior abiraterone, and the main goal is to see if the combination delays cancer growth or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZEN003694 (ZEN-3694) combined with enzalutamide (Xtandi)
What this could lead to
If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a mid-stage trial with only 200 participants, so results may not confirm benefit. The drug combination may cause side effects or fail to improve progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230002, China
-
BRCR Global
RECRUITINGPlantation, Florida, 33322, United States
-
California Research Institute
RECRUITINGLos Angeles, California, 90027, United States
-
Chongqing Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, 400030, China
-
Colorado Urology
RECRUITINGLakewood, Colorado, 80228, United States
-
D&H Cancer Research Center, LLC
RECRUITINGMargate, Florida, 33063, United States
-
First Hospital of Shanxi Medical University
RECRUITINGTaiyuan, Shanxi, 030001, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Hematology Oncology Clinic
WITHDRAWNBaton Rouge, Louisiana, 70809, United States
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, 430079, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410006, China
-
Innovative Clinical Research Institute
RECRUITINGWhittier, California, 90603, United States
-
Liaoning Cancer Hospital
WITHDRAWNShenyang, Liaoning, 110042, China
-
Maryland Oncology Hematology, P.A.
RECRUITINGColumbia, Maryland, 21044, United States
-
Messino Cancer Center
RECRUITINGAsheville, North Carolina, 28806, United States
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, 210008, China
-
Northwest Cancer Specialists, P.C.
RECRUITINGPortland, Oregon, 97223, United States
-
Seattle Cancer Care Alliance
RECRUITINGSeattle, Washington, 98109, United States
-
Shanghai Tenth People's Hospital
RECRUITINGShanghai, Shanghai Municipality, 200072, China
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, 610072, China
-
Texas Oncology - Central South
RECRUITINGAustin, Texas, 78731, United States
-
The First Affiliated Hospital of Xi'an Jiaotang University
RECRUITINGXi'an, Shaanxi, 71000, China
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361003, China
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology
RECRUITINGWuhan, Hubei, 430030, China
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94158, United States
-
University of Michigan Rogel Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Urology Associates, P.C.
RECRUITINGNashville, Tennessee, 37209, United States
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
-
Weill Cornell Medical College - New York Presbyterian Hospital
COMPLETEDNew York, New York, 10065, United States
-
Zhejiang Provincial People's Hospital
RECRUITINGHangzhou, Zhejiang, 310014, China